Debiopharm invests in DTx leader Voluntis

Founded in 2001, Voluntis is a French-US based public company specialized in Digital Therapeutics. Voluntis invents secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-oriented processes. With more than 600,000 patients managed and more than 50 programs deployed.

Our mission is to improve the patient journey and the efficiency of drug development. For that reason, we decided to support Voluntis to help fulfill their vision.

Click here to access to voluntis press release